Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed heart failure management. Recently, clinicians have started investigating the role of SGLT2 inhibitors in AS (aortic stenosis). This common valvular disease currently lacks any disease-modifying pharmacologic treatment. While surgery or transcatheter replacement remains the standard for severe cases, these interventions do not always reverse myocardial remodeling.

Aortic stenosis causes chronic pressure overload, which leads to pathological cardiac changes. These changes include hypertrophy and fibrosis. Consequently, many patients experience persistent heart failure symptoms even after valve intervention. Researchers believe that SGLT2 inhibition could provide a dual benefit by targeting both the valve biology and the heart muscle. Therefore, this drug class offers a promising new direction for valvular heart disease therapy.

Potential Benefits of SGLT2 Inhibitors in AS

Mechanistically, SGLT2 inhibitors demonstrate potent anti-inflammatory and anti-fibrotic properties. Specifically, they may suppress signaling pathways like TGF-β and the NLRP3 inflammasome. These pathways drive the progression of valve calcification and myocardial scarring. Furthermore, recent retrospective studies indicate that patients taking these agents have a lower risk of progressing to severe aortic stenosis. These findings suggest that the drugs might slow the hemodynamic worsening of the valve itself.

Moreover, emerging evidence from the BIO-AS study shows that SGLT2 receptors are actually expressed in the myocardium of patients with severe stenosis. This presence implies a direct site of action for the medication. Currently, dedicated trials are evaluating if drugs like empagliflozin can prevent fibrosis in moderate cases. If these trials succeed, they will establish a new pharmacological standard for managing this aging population.

Frequently Asked Questions

How do SGLT2 inhibitors influence aortic stenosis progression?

Evidence suggests they may reduce inflammation and oxidative stress in valve tissues. This process potentially slows the calcification that leads to valve narrowing. Additionally, they help manage the heart's response to pressure overload.

Can SGLT2 inhibitors be used for patients without diabetes?

In heart failure, SGLT2 inhibitors are already used regardless of diabetes status. For aortic stenosis, researchers are still investigating their specific benefits in non-diabetic populations through ongoing clinical trials.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Mazur P et al. Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis. JACC Basic Transl Sci. 2026 Jun 12. doi: undefined. PMID: 42284627.


2. Shah T et al. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovasc Interv. 2025;18(6):738-748.


3. Scisciola L et al. Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: the BIO-AS study. Eur J Heart Fail. 2024;26(2):471-482.